Figure 3
Figure 3. Overall survival after URD-PBSC transplantation by CD34+ dose. CD34+ cell doses higher than 4.5 × 106/kg recipient weight improved overall survival compared with lower doses. However, doses much higher than 4.5 × 106/kg did not further improve the survival rate compared with doses just above 4.5 × 106/kg. (A) Overall survival after MA transplantation (P = .020 at 3 years for Medium vs Low; P = .489 at 3 years for Medium vs High). (B) Overall survival after RI/NMA transplantation (P = .045 at 3 years for Medium vs Low; P = .157 at 3 years for Medium vs High). Low indicates no greater than 4.5 (n = 142, MA; n = 80, RI/NMA); Medium, 4.5 to 9.5 (n = 183, MA; n = 102, RI/NMA); High, greater than 9.5 (n = 110, MA; n = 54, RI/NMA) (× 106 CD34+/kg).

Overall survival after URD-PBSC transplantation by CD34+ dose. CD34+ cell doses higher than 4.5 × 106/kg recipient weight improved overall survival compared with lower doses. However, doses much higher than 4.5 × 106/kg did not further improve the survival rate compared with doses just above 4.5 × 106/kg. (A) Overall survival after MA transplantation (P = .020 at 3 years for Medium vs Low; P = .489 at 3 years for Medium vs High). (B) Overall survival after RI/NMA transplantation (P = .045 at 3 years for Medium vs Low; P = .157 at 3 years for Medium vs High). Low indicates no greater than 4.5 (n = 142, MA; n = 80, RI/NMA); Medium, 4.5 to 9.5 (n = 183, MA; n = 102, RI/NMA); High, greater than 9.5 (n = 110, MA; n = 54, RI/NMA) (× 106 CD34+/kg).

Close Modal

or Create an Account

Close Modal
Close Modal